Antigen-based T-cell-targeted immunotherapy: recent developments in autoimmunity and allergy

Bibliography

• O'GARRA A, STEINMAN L, GIJBELS K: CD4+ T cell subsets in autoimmunity. Curr. Opin. Immunol. (1997) 9(6)872–883.
   Google Scholar
• WEINER HL: Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol. Today (1997) 18(7):335–343.
   PubMedGoogle Scholar
• XIAO BG, LINK H: Mucosal tolerance: a two-edged sword to prevent and treat autoimmune diseases. Clin. Immunol. Immunopathol (1997) 85 (2):119–128.
   PubMedGoogle Scholar
• MARTINS, WELTZIEN HU: T cell recognition of haptens, a molecular view. Int. Arch. Allergy Immunol. (1994) 104 (1):10–16
   PubMed Web of Science ®Google Scholar
• LU P, WANG YL, LINSLEY PS: Regulation of self-tolerance by CD80/CD86 interactions. Curr. Opin. Im-munol (1998) 9:858–862.
   Web of Science ®Google Scholar
• GUICHARD G: MHC ligands as potential therapeutics in the treatment of autoimmune and allergic diseases. Exp. Opin. Ther. Patents (1997) 7(0:29–42
   Google Scholar
• WILLIAMS N: T cells on the mucosal frontline. Science (1998) 280:198–200
   PubMed Web of Science ®Google Scholar
• KALDEN JR, SIEPER J: Oral collagen in the treatment of rheumatoid arthritis. Arthritis Rheum. (1998) 41 (2) :191–194.
   PubMedGoogle Scholar
• BARNETT ML, KREMER JM, ST CLAIR EW et al.: Treatment of rheumatoid arthritis with oral type II collagen. Re-sults of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. (1998) 41(2)290–297.
   Google Scholar
• STAINES NA, HARPER N, WARD FJ et al.: Mucosal toler-ance and suppression of collagen-induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184-198 of bovine type II collagen (CI) expressing a dominant T cell epitope. Clin. Exp. Immunol (1996) 103 (3):368–375.
   PubMed Web of Science ®Google Scholar
• MYERS LK, SEYER JM, STUART JM et al.: Suppression of murine collagen-induced arthritis by nasal admini-stration of collagen. Immunology (1997) 90(2) :161–164.
   PubMed Web of Science ®Google Scholar
• AL-SABBAGH A, NELSON PA, AKSELBAND Y et al.: Antigen-driven peripheral immune tolerance: sup-pression of experimental autoimmmune encephalo-myelitis and collagen-induced arthritis by aerosol administration of myelin basic protein or type II colla-gen. Cell. Immunol. (1996) 171(0:111–119.
   PubMedGoogle Scholar
• HAQUE MA, YOSHINO S, INADA S et al.: Suppression ofadjuvant arthritis in rats by induction of oral tolerance to mycobacterial 65-kDa heat shock protein. Eur. J. Im-munol (1996) 26(10:2650–2656.
   PubMedGoogle Scholar
• PRAKKEN BJ, VAN DER ZEE R, ANDERTON SM et al. Peptide-induced nasal tolerance for a mycobacterial heat shock protein 60 T cell epitope in rats suppresses both adjuvant arthritis and nonmicrobially induced experimental arthritis. Proc. Natl. Acad. Sci. USA (1997) 94 (7):3284–3289.
   PubMed Web of Science ®Google Scholar
• •Intranasal administration of a microbial T-cell epitope de-rived from hsp60 mediates bystander suppression of avridine-induced arthritis. VERHEIJDEN GF, RIJNDERS AW, BOS E et al.: Human car-tilage glycoprotein-39 as a candidate autoantigen in rheumatoid arthritis. Arthritis Rheum. (1997) 40 (6):1115–1125. The authors have demonstrated that HC gp-39 is a target autoantigen in RA and that nasal administration of the pro-tein suppressed HC gp-39-induced arthritis. DRB1*0401 re-stricted immunodominant T-cell epitopes have also been identified.
   Google Scholar
• FUKAURA H, KENT SC, PIETRUSEWICZ MJ et al.: Induc- tion of circulating myelin basic protein and prote-olipid protein-specific transforming growth factor-betal -secreting Th3 T cells by oral administra-tion of myelin in multiple sclerosis patients. J. Clin. In-vest. (1996) 98(0:70–77.
   PubMedGoogle Scholar
• MUIR A, PECK A, CLARE-SALZLER M et al.: Insulin immu- nization of nonobese diabetic mice induces a protec-tive insulitis characterized by diminished intraislet interferon-gamma transcription. J. Clin. Invest. (1995) 95 (2):628–634.
   PubMed Web of Science ®Google Scholar
• POLANSKI M, MELICAN NS, ZHANG J et al. Oral admini- stration of the immunodominant B-chain of insulin re-duces diabetes in a co-transfer model of diabetes in the NOD mouse and is associated with a switch from Thl to Th2 cytokines. j Autoimmune (1997) 10(4):339–346. HARRISON LC, DEMPSEY-COLLIER M, KRAMER DR et al.: Aerosol insulin induces regulatory CD8 yö T cells that prevent murine insulin-dependent diabetes. J. Exp. Med. (1996) 184(6):2167–2174. The finding that CD8+ y8 T-cells induced with aerosolised insulin can suppress the adoptive transfer of diabetes to non-diabetic mice has implications for the prevention of hu-man IDDM.
   Google Scholar
• DANIEL D, WEGMANN DR: Protection of nonobese dia- betic mice from diabetes by intranasal or subcutane-ous administration of insulin peptide B-(9–23). Proc. Natl. Acad. Sci. USA (1996) 93 (2):956–960. TIAN J, ATKINSON MA, CLARE-SALZLER M et al.: Nasal ad-ministration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J. Exp. Med. (1996) 183(01561–1567. A single nasal administration of a mixture of GAD65 derived peptides prevented development of IDDM in NOD mice. The protective effect was associated with high level of anti-GAD65 IgG1 antibodies, reduced secretion of IFN-y and en-hanced production of IL-5. CONGIA M, PATEL S, COPE AP et al.: T cell epitopes of in-sulin defined in HLA-DR4 transgenic mice are derived from preproinsulin and proinsulin. Proc. Natl. Acad. Sci. USA (1998) 95(7):3833–3838. Identification of a naturally processed immunodominant T-cell epitope from human preproinsulin and proinsulin pre-sented in the context of HLA DRB1*0401 and located be-tween the C peptide and the A chain.
   Google Scholar
• TIAN J, ATKINSON MA, CLARE-SALZLER M et al.: Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J. Exp. Med. (1996) 183(4):1561–1567.
   PubMed Web of Science ®Google Scholar
• • A single nasal administration of a mixture of GAD65 derived peptides prevented development of IDDM in NOD mice. The protective effect was associated with high level of anti- GAD65 IgG1 antibodies, reduced secretion of IFN-g and enhanced production of IL–5.
   Google Scholar
• CONGIA M, PATEL S, COPE AP et al.: T cell epitopes of insulin defined in HLA-DR4 transgenic mice are derived from preproinsulin and proinsulin. Proc. Natl. Acad. Sci. USA (1998) 95(7):3833–3838.
   PubMed Web of Science ®Google Scholar
• • Identification of a naturally processed immunodominant Tcell epitope from human preproinsulin and proinsulin presented in the context of HLA DRB1*0401 and located between the C peptide and the A chain.
   Google Scholar
• WICKER LS, CHEN SL, NEPOM GT et al: Naturally proc- essed T cell epitopes from human glutamic acid decar-boxylase identified using mice transgenic for the type 1 diabetes-associated human MHC class II allele, DRB1*0401. j Clin. Invest. (1996) 98 (11) :2597–2603.
   PubMed Web of Science ®Google Scholar
• •Two immunodominant T-cell epitopes from human GAD65 identified in the DRB1*0401 transgenic mice are located within residues 274–286 and 115–127.
   Google Scholar
• ENDL J, OTTO H, JUNG G et al. Identification of natu- rally processed T cell epitopes from glutamic acid de-carboxylase presented in the context of HLA-DR alleles by T lymphocytes of recent onset IDDM pa-tients. J. Olin. Invest. (1997) 99(10):2405–2415.
   PubMed Web of Science ®Google Scholar
• PATEL. AD, COPE AP, CONGIA, M et al.: Identification ofimmunodominant T cell epitopes of human glutamic acid decarboxylase 65 by using HLA-DR(a1*0101, 61*0401) transgenic mice. Proc. Natl. Acad. Sci. USA (1997) 94: 8082–8087.
   Google Scholar
• NUSSENBLATT RB, GERY I, WEINER HL et al: Treatmentof uveitis by oral administration of retinal antigens: re-sults of a phase I/II randomized masked trial. Am. J. Ophthalmol. (1997) 123(5):583–592.
   PubMed Web of Science ®Google Scholar
• THURAU SR, DIEDRICHS-MOHRING M, FRICKE H et al:Molecular mimicry as a therapeutic approach for an autoimmune disease: oral treatment of uveitis-patients with an MHC-peptide cross-reactive with autoantigen first results. Immunol. Lett. (1997) 57(1-3):193–201.
   PubMed Web of Science ®Google Scholar
• •Preliminary study indicating disease improvement in uveitis patients treated by oral administration of an HLA-B27 pep-tide cross reactive with the major epitope of S antigen.
   Google Scholar
• HANEDA K, SANO K, TAMURA G et al.: TGF-beta induced by oral tolerance ameliorates experimental tracheal eosinophilia. j Immunol. (1997) 159 (9) :4484–4490.
   PubMed Web of Science ®Google Scholar
• VAN HALTEREN AG, VAN DER CAMMEN MJ, COOPER D et al: Regulation of antigen-specific IgE, IgGl, and mast cell responses to ingested allergen by mucosal toler- ance induction. J. Immunol. 1997 159(6):3009–3015
   PubMed Web of Science ®Google Scholar
• BROCKE S, GIJBELS K, ALLEGRETTA M et al Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature (1996) 379(6563) 343–346
   PubMed Web of Science ®Google Scholar
• NICHOLSON LB, GREER JM, SOBEL RA et al: An alteredpeptide ligand mediates immune deviation and pre-vents autoimmune encephalomyelitis. Immunity (1995) 3 (4):397–405.
   PubMed Web of Science ®Google Scholar
• MATSUOKA T, KOHROGI H, ANDO Metal: Altered TCRligands affect antigen-presenting cell responses: up-regulation of IL-12 by an analogue peptide. J. Immunol. (1996) 157(10:4837–4843.
   PubMedGoogle Scholar
• AUSUBEL LJ, KRIEGER JI, HAFLER DA: Changes in cyto-kine secretion induced by altered peptide ligands of myelin basic protein peptide 85-99. J. Immunol. (1997) 159(5) :2502–2512.
   PubMed Web of Science ®Google Scholar
• WINDHAGEN A, SCHOLZ C, HOLLSBERG P et al. Modula- tion of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their pep-tide ligand. Immunity (1995) 2(4):373–380.
   PubMed Web of Science ®Google Scholar
• NICHOLSON LB, MURTAZA A, HAFLER BP et al: A T cell receptor antagonist peptide induces T cells that medi-ate bystander suppression and prevent autoimmune encephalomyelitis induced with multiple myelin anti-gens. Proc. Natl Acad. Sci. USA (1997) 94(17):9279–9284.
   PubMed Web of Science ®Google Scholar
• •[Leu144, Arg147] PLP (139–151), a TCR antagonist of encepha-litogenic Thl clones in vitro can induce Th2 cells in vivo that mediate bystander suppression of EAE caused by unrelated myelin encephalitogens.
   Google Scholar
• KATZ-LEVY Y, PAAS-ROZNER M, KIRSHNER S et al.: A pep-tide composed of tandem analogs of two myastheno-genic T cell epitopes interferes with specific autoimmune responses. Proc. Natl. Acad. Sci. USA (1997) 94 (7):3200–3205.
   PubMed Web of Science ®Google Scholar
• GAUR A, BOEHME SA, CHALMERS D et al.: Ameliorationof relapsing experimental autoimmune encephalo-myelitis with altered myelin basic protein peptides in-volves different cellular mechanisms. J. Neuroimmunol (1997) 74(1-2):149–158.
   PubMed Web of Science ®Google Scholar
• COMBADIERE B, ESOUSA CR, GERMAIN RN et al.: Selec-tive induction of apoptosis in mature T lymphocytes by variant T cell receptor ligands. J. Exp. Med. (1998) 187(3)349–355.
   Google Scholar
• •Demonstration that TCR engagement by APL can lead to T-cell apoptosis via the expression of FasL and TNF.
   Google Scholar
• PEARSON CI, VAN EWIJK W, MCDEVITT HO: Induction ofapoptosis and T helper 2 (Th2) responses correlates with peptide affinity for the major histocompatibility complex in self-reactive T cell receptor transgenic mice. J. Exp. Med. (1997) 185(4):583–599.
   PubMed Web of Science ®Google Scholar
• GELBER C, GEMMELL L, MCATEER D, HOMOLA M, SWAIN P, LIU A, WILSON J, GEFTER M: Down-regulation of poi-son ivy/oak-induced contact sensitivity by treatment with a class II MHC binding peptide:hapten conjugate. Immunol. (1997) 158: 2425:2434.
   Google Scholar
• ••Design of a peptide carrier with high MHC binding capacityand minimal TCR contact area to optimise hapten presenta-tion. Administration of a peptide carrier:PDC conjugate in a non-immunogenic fashion down-regulates PDC-induced DTH.
   Google Scholar
• KOHLER J, HARTMANN U, GRIMM R, PFLUGFELDER U,WELTZIEN HU: Carrier-independent hapten recogni-tion and promiscuous MHC restriction by CD4 T cells induced by trinitrophenylated peptides. J. Immunol (1997) 158:591–597.
   PubMed Web of Science ®Google Scholar
• PADOVAN E, BAUER T, TONJIO MM, KALBACHER H, WELTZIEN HU: Penicilloyl peptides are recognized as T cell angenic determinats in penicillin allergy. Eur. Immunol (1997) 27:1303–1307.
   PubMed Web of Science ®Google Scholar
• •First demonstration of penicilloyl-peptides recognition by human CD4+ T-cells.
   Google Scholar
• GOLDSTEIN J, MOSTOWSKY H, TUNG J, HON H, BRUNS- WICK M, KOZLOWSKI S: Naive alloreactive CD8 T cells are activated by purified major histocompatibility complex class I and antigenic peptide. Eur. J. Immunol (1997) 27: 871–878.
   PubMed Web of Science ®Google Scholar
• •This study demonstrates that soluble MHC/peptide com-plexes can trigger naive CD8+ T-cells into a fully activated state.
   Google Scholar
• NAG B, KENDRICK T, ARIMILLI S, YU SCT, SRIRAM S: Solu-ble MHC II-peptide complexes induce antigen-specific apoptosis in T cells. Cellular Immunol (1996) 170:25–33.
   PubMed Web of Science ®Google Scholar
• CUNNINGHAM NR, RIVETNA M, TOLMAN RL et al.: SAR for MHC class II binding tetrapeptides: correlation with potential binding site. Bioorg. Med. Chem. Lett. (1997) 7(0:19–24.
   Google Scholar
• JONES AB, ACTON JA, CUNNINGHAM BC et al.: Inhibition of MHC class II ligation by peptidomimetics: prospects for antigen specific immunosuppression. 14th Interna-tional Medical & Chemical Symposium. Maastricht, Nether-lands (1998).
   Google Scholar
• WOULFE SL, BONO CP, ZACHEIS ML et al.: A peptidomi-metic that specifically inhibits human leukocyte anti-gen DRB1*0401-restricted T cell proliferation. J. Pharmacol. Exp. Ther. (1997) 281(2):663–669.
   PubMed Web of Science ®Google Scholar
• MONJI T, PIOUS D: Exogenously provided peptides fail to complex with intracellular class II molecules for presentation by antigen-presenting cells. J. Immunol. (1997) 158(7):3155–3164.
   PubMed Web of Science ®Google Scholar
• WAUBEN MH, HOEDEMAEKERS AC, GRAUS YM et al.: In-hibition of experimental autoimmune myasthenia gravis by major histocompatibility complex class II competitor peptides results not only in a suppressed but also in an altered immune response. Eur. j Immu-nol. (1996) 26(12):2866–2875.
   PubMed Web of Science ®Google Scholar
• GHOSH P, AMAYA M, MELLINS E et al.: The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature (1995) 378(6556):457–462.
   PubMed Web of Science ®Google Scholar
• SEEBACH D, POENARU S, FOLKERS G et al.: Synthesis of 3-hydroxybutanoate-peptide conjugates with high binding affinity to a class I MHC protein. (1998). (Sub-mitted).
   Google Scholar
• BIANCO A, ZABEL C, WALDEN P et al N-Hydroxy-amide analogues of MHC-Class I peptide ligands with nano-molar binding affinities. J. Peptide. Sci. (1998). (In Press).
   Google Scholar
• BLANAS E, CARBONE FR, ALLISON J et al.: Induction of autoimmune diabetes by oral administration of auto-antigen. Science (1996) 274(5293):1707–1709.
   PubMed Web of Science ®Google Scholar
• BAI XF, LI HL, SHI FD et al.: Complexities of applying na-sal tolerance induction as a therapy for ongoing re-lapsing experimental autoimmune encephalomyelitis (EAE) in DA rats. Orin. Exp. Immunol (1998) 111(0:205–210.
   PubMedGoogle Scholar